Formulation and evaluation of extended release tablets of Diltiazem hydrochloride

Sharma, Garima; Verma, Vinay Sagar; Sharma, Mukesh; Chandrakar, Sandhya; Gupta, Sujata; Solanki, Harsha; Dewangan, Kalyani; Sahu, Vandana Devi; Majumdar, Manisha; Tripathi, D. K.; Alexander, Amit; AJAZUDDIN, .

doi:10.5958/0974-360x.2016.00150.5

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diltiazem hydrochloride, which is a calcium ion cellular influx inhibitor (slow channel blocker or calcium antagonist), does provide therapeutic benefits mainly related to its ability to inhibit calcium ions influx during membrane depolarization of cardiac and vascular smooth muscle of cardiac and vascular system. 1 Diltiazem HCl is predominantly used for the treatment of specific cardiovascular ailments. Its therapeutic impacts are associated with its capacity to lower the flood of calcium ions in cardiovascular and vascular smooth muscle, during membrane depolarization.…”

Section: Introductionmentioning

confidence: 99%

Understanding Degradation Pathway of Poorly Stable Diltiazem Hydrochloride and Development of its Stabilized Controlled-release Tablets

Agrawal¹,

Mishra²,

Bansal³

2022

IJDDT

View full text Add to dashboard Cite

Diltiazem hydrochloride is a class -1 drug, as per the breast-conserving surgery (BCS) classification system, which is highly soluble and highly permeable. It is a poorly stable drug that poses many problems during formulation preparation. The stability of the final product is quite challenging. The API undergoes hydrolysis to form desacetyl-diltiazem. It is the major degradation impurity. Desacetyl-diltiazem exhibits only a quarter to half of the pharmacological activity as compared to diltiazem HCl. A correct understanding of the degradation pathway and usage of suitable excipients can provide a stable product with improved shelf life. During the course of various trials and application of factorial designing, an optimized composition for oral controlled release tablets of diltiazem HCl has arrived, suggesting that exposure to an aqueous medium for tablets granulation and eliminating the polyvinylpyrrolidone from the composition significantly improved the product stability and final tablets shelf life by not only maintaining the desired in-vitro drug release profile but also keeping the related substances (impurities level) at very low levels throughout the entire shelf life.

show abstract

Section: Introductionmentioning

confidence: 99%